André Bergman has been working as an oncologist at the Netherlands Cancer Institute as of 2008, where he also leads a research group. His work is entirely dedicated to prostate cancer. He connects fundamental research and clinical practice, and applies his laboratory findings in the clinic. André: “The goal is to understand the effectiveness of drugs in prostate cancer patients and to provide them with improved treatments.”
In the lab, André investigates gene regulation in the prostate, which is largely determined by the activity of androgen receptors in prostate cancer cells. His clinical research focuses on drugs that inhibit these receptors and on new agents that influence gene regulation in other ways. André is a board member of various national study groups, registration, and guideline committees as well. He works on regional collaboration for the treatment of prostate cancer as part of the Prostate Cancer Network (PKNW) and OncoNovo+. André: “Regional collaboration is the future. It leads to better quality and availability of care and lower costs.”
As a professor, André will promote collaboration between the NKI, and AmsterdamUMC in the field of prostate cancer care and research. He will also encourage cooperation in the north-west of the Netherlands for the care of prostate cancer patients.